New therapy wins EMA orphan drug designation for ALS
pharmafile | August 9, 2016 | News story | Manufacturing and Production, Research and Development | EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation
French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, through inhibiting a limited number of kinases. AB Science indicates its mode of action makes is a candidate in oncology, inflammatory disease and in certain diseases of the central nervous system. It has performed well in trials for the degenerative ALS, which causes muscles to decrease in size.
In ongoing Phase II/III trials, masitinib was used in combination with riluzole and showed significant benefits in an interim analysis compared to riluzole alone. There is, of yet, no cure for the disease but treatment riluzole can extend life by several months. It has already been approved in the EU.
AB Science has welcomed the EMA’s orphan drug designation, highlighting how stringently the EMA administers the designation, compared to the US FDA. To qualify, AB Science had to demonstrate significant benefits that could be derived from masitinib, as well as demonstrate its efficacy alongside riluzole. The drug has already been granted orphan status by the FDA.
Alain Moussy, CEO at AB Science, says: “The granting of this orphan drug status is one more positive milestone from EMA after acceptance of the filing for conditional marketing authorisation, still planned in September 2016.”
ALS recently gained much notoriety due to the ubiquitous Ice Bucket Challenge, which filled our social media timelines around two years ago. It raised well over $100 million for the ALS research. Recently, it emerged that some of the funding used helped researchers make new genetic discoveries, as to how the disease develops.
Sean Murray
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and …
NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence …
